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Abstract Apoptotic cells activate homologous complement and 
are opsonized with iC3b. We assessed the effect of iC3b 
opsonization upon phagoqtosis of apoptotic Jurkat cells by 
macrophages, which were differentiated from THP-1 cells by 
treatment with retinoic acid. Macrophage phagocytosis of 
apoptotic Jurkat cells was enhanced upon incubation of the 
apoptotic cells with normal human serum. The enhanced 
macrophage phagocytosis of normal serum-treated apoptotic 
cells was decreased by anti-human C3 F(ab’)t and anti-CR3 and 
anti-CR4 mAbs to the level of phagocytosis of those treated with 
complement-blocked serum. These results suggest that interac- 
tion between iC3b on apoptotic cells and complement receptor 
type 3 (CR3) and/or complement receptor type 4 (CR4) on 
macrophages could play an important role for the clearance of 
apoptotic cells by macrophages in vivo. 
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1. Introduction 
One of the characteristics of apoptosis, a kind of pro- 
grammed cell death, is the rapid phagocytosis by macrophages 
of apoptotic cells before they are lysed to induce inflammatory 
responses [l]. Apoptosis is known to be accompanied by sur- 
face changes that allow recognition and removal of these cells 
by macrophages. Three types of molecules on macrophages 
have been proposed to be involved in recognition and proc- 
essing of apoptotic cells: asialoglycoprotein receptors [2], 
thrombospondin receptors [3], and phosphatidylserine recep- 
tors [4]. Asialoglycoprotein receptors recognize side chain su- 
gars, which become exposed by the release of sialic acid. 
Thrombospondin receptors, such as vitronectin receptors 
and CD36, recognize thrombospondin bound to the throm- 
bospondin-binding moiety on apoptotic cells. Phosphatidyl- 
serine receptors bind phosphatidylserine, which becomes ex- 
posed from the inner membrane to the outer membrane upon 
apoptosis. Although complement receptors such as CR3 and 
CR4 are known to play an important role in macrophage 
phagocytosis [5], little attention has been paid to the role of 
these molecules in phagocytosis of apoptotic cells. 
Complement is a humoral immune system composed of two 
cascades termed the classical and alternative pathways [6]. 
Nascent C3b which has a labile binding site is produced 
upon activation of both complement pathways and binds 
covalently to the target cell membrane [7]. Most C3b on the 
target cells is rapidly cleaved by the serum protease factor I 
into iC3b [8], which is the ligand of the complement receptors, 
CR3 and CR4. Phagocytes such as neutrophils and macro- 
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phages rapidly ingest the iC3b-opsonized target cells through 
CR3 and CR4 [5]. 
We have reported that apoptotic human cells can activate 
the alternative pathway of human complement and become 
opsonized with iC3b [9,10]. It was expected that iC3b-CR3 
interaction would promote the binding of iC3b-opsonized 
apoptotic cells to macrophages and subsequently enhance 
macrophage phagocytosis of iC3b-opsonized apoptotic cells. 
Here, we report that iC3b deposited on apoptotic Jurkat cells, 
a human T lymphoma cell line, can induce CR3-dependent 
phagocytosis by macrophages, which were differentiated from 
THP-I cells by retinoic acid treatment. 
2. Materials and methods 
2.1. Materials 
Anti-Fas mAb (clone CH-11) was obtained from Medical and Bio- 
logical Lab. Fluorescein isothiocyanate (FITC)-conjugated goat 
F(ab’)* anti-mouse IgG was obtained from American Qualex Inter- 
national. Goat F(ab’)l anti-human C3 and goat F(ab’)z anti-mouse 
IgG were obtained from Organon Teknika. Anti-CR3 mAb (clone 
44), anti-CR4 mAb (clone 3.9), FITC, and retinoic acid were obtained 
from Sigma. Anti-iC3b mAb (clone C5-G) was a gift from Dr. K. 
Iida, Discovery Research Laboratories, Takeda Chemical Industries. 
Actinomycin D and cycloheximide were obtained from Wako Pure 
Chemicals and ICN Biomedicals, respectively. 
2.2. Cell culture 
Jurkat cells (E6-I), a human T lymphoma cell line, were obtained 
from ATCC, and the human monocytic leukemia cell line, THP-1, 
was obtained from JCRB. These cell lines were cultured in RPMI- 
1640 medium, containing 5% heat-inactivated fetal bovine serum 
(FBS), 100 IU/ml penicillin G and 100 &ml streptomycin. 
2.3. Induction of apoptosis and FITC-labeling of apoptotic cells 
Jurkat cells (5X 106/ml) were induced to undergo apoptosis by in- 
cubation with cycloheximide (30 FM), anti-Fas (50 ng/ml), or anti-Fas 
(50 ng/ml) plus actinomycin D (100 nM) for 16 h at 37°C. The cells 
were washed with phosphate-buffered saline containing 10 mM EDTA 
(EDTA-PBS), and apoptotic cell death was confirmed by agarose gel 
electrophoresis of the DNA fraction. For FITC labeling of apoptotic 
cells, the cycloheximide-treated apoptotic cells were washed with 50 
mM HEPES-buffered saline (HBS), pH 8.5, and the cells (1 X 107/ml) 
were incubated in HBS (pH 8.5) containing 4 @ml FITC and 0.04% 
dimethyl sulfoxide for 10 min at 37°C. The FITC-treated cells were 
then washed with HBS (pH 7.0) and Verona1 buffered saline, contain- 
ing 0.15 mM CaClz and 1 mM MgCls (Vet+), and used as FITC- 
apoptotic cells. 
2.4. Differentiation of THP-1 cells into macrophage-like cells 
THP-1 cells (5 X 105/ml) were incubated with RPMI-1640 contain- 
ing 5”/0 FBS and retinoic acid (1 PM) for 4 days at 37°C. Retinoic 
acid-treated THP-1 cells were collected and washed with EDTA-PBS 
and FBS-free RPMI-1640. The washed cells were suspended in FBS- 
free RPMI-1640 (2.5X 106/ml) and used as macrophages. 
2.5. Measurement of phagocytosis by jopow cytometry 
FITC-apoptotic cells were incubated for 20 min at 37°C with nor- 
mal human serum, heat-inactivated (56°C for 30 min), or EDTA- 
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treated serum (10 mM EDTA in 90% human serum). These cells were 
washed with VB++, suspended in RPMI-1640, and incubated with 
macrophages (5X lo5 cells) in 24-well plates in RPMI-1640, contain- 
ing 10% heat-inactivated human serum, at 37°C. Then, each well was 
washed with PBS containing 0.1% BSA and 0.1% sodium azide to 
remove the FITC-apoptotic cells that did not bind with macrophages. 
Macrophages adhering to the 24-well plates were then harvested by 
pipetting with the same buffer and suspended in 50 mM acetate buf- 
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Fig. 1. A: DNA fragmentation in Jurkat cells treated with anti-Fas 
mAb or cycloheximide. Jurkat cells were incubated with anti-Fas 
mAb (lane 3), anti-Fas mAb plus actinomycin D (lane 4), or cyclo- 
heximide (lane 5) for 18 h at 37°C. Lane 2 was non-treated Jurkat 
cells. DNA was extracted from these cells and the DNA (5 ug) was 
resolved by electrophoresis in an agarose gel. Lanes 1 and 5 show 
molecular weight markers (Lambda/Hind111 digest and pUC/HinfI 
digest), and molecular weight is expressed in terms of kilo base 
pairs. B: iC3b deposition on apoptotic Jurkat cells upon treatment 
with human serum. Live cells and apoptotic cells in (A) were incu- 
bated with normal human serum for 30 min at 37°C. iC3b deposi- 
tion was measured with anti-iC3b mAb (clone C5-G) by flow cy- 
tometry. The vertical axis shows the cell number and the horizontal 
axis shows fluorescence intensity. 
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Fig. 2. A: Effect of apoptotic cell/macrophage ratio upon macro- 
phage phagocytosis of apoptotic cells. Macrophages (5 X lo5 cells) 
were incubated in medium (0.4 ml) for 2 h with apoptotic cells 
(2.5515 x lo6 cells) treated with EDTA-serum (EDTA-HS; q ), heat- 
inactivated serum (HI-HS; o), or normal serum (NHS; 0). Values 
of phagocytosis are expressed as mean fluorescence intensity and as 
the means f SD of triplicate determinations. These experiments were 
each repeated three times with similar results. B: Time course of 
macrophage phagocytosis of serum-treated apoptotic cells. Macro- 
phages (5 x lo5 cells) were incubated for 0, 1, 2, 3, and 4 h with 
apoptotic cells (8X lo6 cells) treated with EDTA-serum (EDTA- 
HS), heat-inactivated serum (HI-HS), or normal serum (NHS). 
Values of phagocytosis are expressed as mean fluorescence intensity 
and as the means? SD of triplicate determinations. These experi- 
ments were each repeated three times with similar results. 
fered saline (pH 4.5). To quench fluorescence due to FITC-apoptotic 
cells, which were not internalized by macrophages, trypan blue (2 mg/ 
ml) was added, and the fluorescence due to the internalized-FITC was 
rapidly determined by flow cytometry (EPICS-CS; Coulter) [11,12]. 
Fluorescence microscopic analysis confirmed that the fluorescence of 
FITC-apoptotic cells binding at the macrophage surface was com- 
pletely quenched by the pretreatment with trypan blue. To examine 
the effect of anti-human C3 F(ab’)z upon phagocytosis, serum-treated 
FITC-apoptotic cells in PBS containing 0.1% BSA and 0.1% sodium 
azide were preincubated with 10 ug/ml goat anti-human C3 F(ab’)s 
for 30 min at 4’C, washed, and incubated with macrophages. 
3. Results 
Previously, we used anti-Fas mAb to induce apoptosis of 
Jurkat cells [lo]. mAb-Treated apoptotic cells can be phago- 
cytosed through FcR and thus seemed to be unfavorable for 
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have been described for macrophage recognition of apoptotic 
cells [ 11. These studies focused on direct recognition of ligands 
exposed on apoptotic cells by macrophage and did not take 
into consideration that apoptotic cells may come into contact 
with interstitial fluids and thus may be opsonized with serum 
proteins. Thus, most studies of phagocytosis by macrophages 
of apoptotic cells were performed in the absence of serum [2- 
4]. We have reported previously that apoptotic cells can acti- 
vate homologous complement and are opsonized with iC3b 
[9,10]. It seemed likely that the interaction between iC3b and 
CR3 and/or CR4 would augment the recognition and proc- 
essing of apoptotic cells by macrophages. The present study 
demonstrated a fourth mechanism for removal of apoptotic 
cells: phagocytosis by macrophages of iC3b-opsonized apop- 
totic cells through CR3 and/or CR4. 
In the present study, we used cycloheximide to induce apop- 
tosis of Jurkat cells. Cycloheximide has been reported to show 
dual effects on apoptosis: it inhibits fibroblast growth factor- 
induced apoptosis of endothelial cells [16], while it augments 
anti-Fas-induced apoptosis of the sarcoma cell line A673 [17]. 
We observed that cycloheximide can induce apoptosis of Jur- 
kat cells and that the cycloheximide-induced apoptotic Jurkat 
cells acquired the ability to activate the human alternative 
complement pathway, similarly to those induced by anti-Fas 
mAb. 
Macrophages, which were differentiated from THP-1 cells 
by retinoic acid treatment, phagocytosed cycloheximide-in- 
duced apoptotic Jurkat cells only poorly, unless they were 
treated with normal or heat-treated serum. The enhanced pha- 
gocytosis by macrophages of normal serum-treated apoptotic 
cells was decreased by anti-C3 F(ab’)e or anti-CR3 and anti- 
CR4 mAbs to the level of phagocytosis of apoptotic cells, 
which had been treated with complement-blocked serum. 
Thus, the interaction between CR3 and/or CR4 and iC3b 
seems to be operative in phagocytosis of normal serum-treated 
apoptotic cells by macrophages. However, this finding ap- 
peared to be contradictory to the reports that blockage with 
monoclonal antibodies to macrophages CR3 and CR4 failed 
to affect macrophage phagocytosis of apoptotic cells [18,19]. 
However, the difference in the effect of anti-CR3 antibody 
upon macrophage phagocytosis of apoptotic cells can partly 
be explained by the difference in the experimental conditions 
in that the apoptotic cells were treated with diluted serum in 
the previous studies (< 10%). We observed that effective iC3b 
deposition on apoptotic cells through the alternative pathway 
can occur in the presence of the serum concentrations higher 
than 20% [9]. Thus, effective complement activation did not 
proceed on apoptotic cells, and consequently CR3-iC3b inter- 
action was not operative in the recognition of apoptotic cells 
by macrophages. 
The present findings do not exclude the roles of other re- 
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ceptors on macrophages in phagocytosis of serum-treated 
apoptotic cells. We observed that macrophage phagocytosis 
of apoptotic cells was also enhanced upon treatment of apop- 
totic cells with complement-blocked serum, i.e., that treated 
with heat or EDTA. The opsonic effect of complement- 
blocked serum may represent the presence of additional op- 
sonic factors. 
We reported that CR3 and FcRII on neutrophils act co- 
operatively in the phagocytosis of iC3b-opsonized immune 
complexes [20]. Thus, it remains to be clarified whether the 
interaction between CR3 and iC3b itself can induce macro- 
phage phagocytosis or augments the phagocytic response 
through other ligand-receptor interactions. 
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